Negative Pressure Wound Therapy (NPWT): A Clinical and Operational Guide for Wound Care Providers

Few wound therapies have transformed wound care like negative pressure wound therapy. Once an experimental technique introduced in the 1990s by Argenta and Morykwas, NPWT is now standard of care for a wide range of chronic wounds, surgical dehiscences, traumatic injuries, and skin grafts. The clinical evidence base is well established, the supply ecosystem is mature, and Medicare and most commercial payers have stable coverage policies.

Despite that maturity, NPWT remains widely misused in practice. Common failure modes include applying it to wounds where it is contraindicated, leaving it on too long, terminating it too early, setting suboptimal parameters, or skipping the wound bed preparation that the therapy requires to work. Misapplication is not a minor problem -- in the wrong wound, NPWT can mask worsening infection, cause significant bleeding, or simply fail to heal an inadequately perfused wound while the patient and the clinical team wait.

This guide is a clinical and operational reference for NPWT -- mechanism, indications, contraindications, application, monitoring, billing, and the documentation infrastructure that supports it. It is written for wound care nurses, podiatrists, surgeons, and program directors who manage NPWT across the continuum of care.

How Negative Pressure Wound Therapy Works

NPWT applies sub-atmospheric (negative) pressure to a sealed wound dressing via a vacuum pump and tubing. The dressing -- foam or gauze, depending on the wound and the manufacturer -- conforms to the wound bed, and the negative pressure (typically -125 mmHg) is delivered continuously or intermittently.

The clinical effects of NPWT are produced through four primary mechanisms:

• Macrodeformation. Negative pressure draws the wound edges inward, contracting the wound and reducing the overall surface area that must be healed. Visible wound contraction is one of the earliest observable signs that NPWT is working.
• Microdeformation. At the cellular level, the mechanical stress produced by negative pressure on tissue stimulates granulation tissue formation. This is the mechanism most often underexplained in clinical summaries of NPWT, and it is the reason granulation appears faster under NPWT than under conventional dressings.
• Exudate removal. Continuous removal of fluid, exudate proteins, and inflammatory mediators from the wound bed. This both reduces edema in the periwound tissue and removes substances that impede healing.
• Bioburden reduction. Reduction in wound bacterial load. The magnitude of this effect is debated in the literature, but a clinical reduction in surface bioburden is consistently observed.

The original mechanistic research published by Argenta and Morykwas in 1997 framed NPWT as a single intervention that combines mechanical, physiologic, and microenvironmental effects -- which is why it produces results that conventional dressing strategies do not match in comparable wounds.

Indications for NPWT

NPWT has earned a place across multiple wound categories. Indications fall into three broad groups:

Acute wounds.

• Surgical wounds, particularly dehisced wounds and high-risk closures.
• Traumatic wounds, including degloving injuries and crush injuries with significant soft-tissue loss.
• Skin grafts -- NPWT applied as a bolster improves graft take rates.

Chronic wounds.

• Pressure injuries, Stage 3 and Stage 4, with adequate vascular supply.
• Diabetic foot ulcers, after debridement, with adequate perfusion and controlled infection.
• Venous leg ulcers, as an adjunct to compression therapy in select cases (typically large, exudative, or non-progressing wounds).

Surgical applications.

• Closed-incision NPWT (ciNPWT) over high-risk surgical closures, increasingly used prophylactically.
• Sternal wound dehiscence.
• Abdominal wound dehiscence and open abdomen management.

The increasingly common prophylactic use of ciNPWT over closed surgical incisions in high-risk patients deserves separate mention. The evidence base is still maturing, but in patients with risk factors for surgical site infection (high BMI, diabetes, vascular surgery, lymph node dissection), ciNPWT has shown meaningful reductions in dehiscence and infection rates.

Contraindications and When NOT to Use NPWT

This section is the most important one in the guide. Misapplication of NPWT is the most preventable category of wound care complication that this therapy produces.

Absolute contraindications.

• Untreated osteomyelitis. NPWT applied over a bone infection that has not been debrided and treated can drive progression while masking the clinical picture.
• Untreated infection in the wound. NPWT can MASK signs of worsening infection if applied without adequate debridement and appropriate antibiotic therapy. The clinical team may believe NPWT is "working" because the dressing seal looks intact, while the underlying infection progresses unobserved between dressing changes.
• Necrotic tissue with eschar. Debride first. NPWT does not eat eschar.
• Malignancy in the wound bed. NPWT may accelerate cell proliferation.
• Exposed blood vessels, organs, or anastomotic sites without appropriate barrier protection. Exposed vasculature plus negative pressure is a bleeding event waiting to happen.
• Non-enteric and unexplored fistulas.

Relative contraindications and cautions.

• Patients on therapeutic anticoagulation. NPWT is not contraindicated but bleeding risk is elevated; setup and monitoring must account for it.
• Friable wound beds with significant bleeding risk.
• Inadequate vascular supply. NPWT does not, and cannot, heal an ischemic wound. Address perfusion first.

Why the contraindications section gets its own emphasis: in a busy wound care service, the pressure to "do something" can drive NPWT placement onto wounds that need a different intervention first. Documented contraindication screening on every NPWT order protects both the patient and the clinical record.

Setting Up NPWT: Application Best Practices

The most common cause of NPWT failure is not therapy choice -- it is application execution. A few practices separate consistent NPWT outcomes from inconsistent ones.

Pre-application.

• Adequate debridement of slough, eschar, and necrotic tissue. The wound bed should be granulating or capable of granulating.
• Hemostasis confirmed before applying the dressing and starting suction.
• Periwound skin protection with a skin prep barrier film. This single step prevents most cases of periwound maceration.

Dressing selection.

• Black polyurethane foam. The most common NPWT dressing. Aggressively promotes granulation; appropriate for deeper wounds requiring tissue fill.
• White polyvinyl alcohol foam. Less aggressive; appropriate for tunneling wounds, wounds near vital structures, or patients whose wounds have been overly aggressive on black foam.
• Antimicrobial-impregnated gauze. An alternative to foam for irregular wound geometries and certain clinical preferences.
• Bridging. When a wound is in an awkward anatomical location that is difficult to seal, foam can be cut and bridged to move the seal to a flatter surface.

Therapy parameters.

• Standard target pressure is -125 mmHg for most chronic wounds.
• Continuous suction for the first 48 hours, often transitioned to intermittent suction thereafter to improve patient comfort and reduce dressing-change pain.
• Dressing change frequency is typically every 48 to 72 hours, individualized to wound and exudate.

Common application errors.

• Inadequate seal. The single most common cause of failed NPWT setups -- the audible "hissing" pump is the giveaway. Re-prep, re-drape, and re-establish seal.
• Over-aggressive foam packing causing pain or producing a pressure injury under the foam against adjacent tissue.
• Skipping periwound skin protection, leading to maceration that can be mistaken for wound deterioration.

Monitoring NPWT and Recognizing Problems

NPWT is not a "set and forget" therapy. Each dressing change is a clinical assessment opportunity.

At every dressing change.

• Wound bed appearance: granulation tissue percentage, slough, eschar, exposed structures.
• Wound dimensions: expect approximately 5 to 10 percent area reduction per week if therapy is effective.
• Periwound skin: maceration, erythema, induration.
• Exudate in the canister: quantity, color, character (purulent change is a red flag).

Signs NPWT is working.

• Granulation tissue forming and filling the wound from the base upward.
• Wound contracting (edges drawing inward).
• Exudate volume decreasing over time.
• No signs of infection.

Signs of failure or complication.

• Worsening pain. NPWT should not produce escalating pain over time; if pain is increasing, reassess.
• Increased exudate or a change to purulent character.
• Periwound erythema, warmth, or systemic infection signs.
• No measurable progress after 2 to 4 weeks despite confirmed adequate setup. At this point reassess for ischemia, occult infection, or alternative therapy.

When to discontinue.

• The wound has reached a point where standard dressings can complete healing -- typically when granulation tissue fills the wound bed. NPWT is not run to wound closure; it is run to a closure-ready wound bed.
• The wound is not progressing despite adequate setup and 4 weeks of therapy.
• Adverse events: bleeding, infection, intolerance.

NPWT in Different Care Settings

NPWT runs across the continuum of care, with different operational dynamics in each setting:

• Hospital. Inpatient initiation, dressing changes by trained nursing staff, daily monitoring, immediate response to alarms or complications.
• Outpatient wound care center. Scheduled dressing changes (often two to three times weekly), less frequent monitoring between visits, patient self-monitoring between appointments.
• Home health. An increasingly common setting. Requires patient and caregiver education, visiting nurse for dressing changes, and remote monitoring of pump alarms. The home setting succeeds when patient selection, education, and visit frequency are all aligned.
• Skilled nursing facility. Trained SNF staff manage day-to-day care; visiting wound care providers handle dressing changes, advanced management, and clinical decisions. Documentation continuity between the SNF team and the visiting wound care provider is the operational make-or-break.
• Single-use disposable NPWT. A growing category for smaller wounds, ambulatory patients, and shorter therapy duration. Eliminates the traditional pump and reduces operational complexity, at the cost of higher per-day supply cost. Particularly common in post-surgical and outpatient settings.

Billing and Reimbursement for NPWT

NPWT billing splits across professional services (CPT) and DME (HCPCS). Both must be coded and documented separately.

CPT codes.

• 97605. NPWT with durable medical equipment; total wound surface area 50 square centimeters or less.
• 97606. NPWT with durable medical equipment; total wound surface area greater than 50 square centimeters.
• 97607. NPWT using single-use, disposable equipment; total wound surface area 50 square centimeters or less.
• 97608. NPWT using single-use, disposable equipment; total wound surface area greater than 50 square centimeters.

DME and supplies.

• E2402. NPWT pump (rental or purchase).
• A6550. NPWT canister.
• A6551. NPWT dressing kit.

Additional HCPCS codes apply to specific supplies depending on manufacturer and configuration.

Coverage and prior authorization. Medicare covers NPWT with documented medical necessity, generally requiring failed conventional therapy and specific covered wound types (Stage 3 and 4 pressure injuries, dehisced surgical wounds, traumatic wounds, qualifying DFUs, and certain other categories). LCD specifics vary by MAC region. Most commercial payers require prior authorization before initiation, and many require ongoing documentation of weekly progress to continue authorization.

Documentation requirements. Wound dimensions at initiation and at each ongoing session, therapy settings (pressure level, continuous or intermittent mode), wound bed response, periwound assessment, and total therapy duration. Progress documentation -- particularly measurable area reduction or granulation tissue increase -- is what supports continuation of authorization and prevents mid-therapy denials.

V3 Biomedical's wound care platform supports NPWT end-to-end. Documentation templates align with CPT requirements at the point of care. Integrated DME tracking ties pump and supply use to the clinical record. Prior authorization workflow support reduces the operational drag that typically slows NPWT initiation. And the unified record means visiting wound care providers, SNF staff, home health nurses, and outpatient clinicians are all documenting against the same patient picture, not three different ones.

For the full CPT context, including modifier rules and documentation requirements that prevent denials across wound care procedures, see the dedicated wound care CPT codes reference.

Frequently Asked Questions

How does negative pressure wound therapy work?

NPWT works through four primary mechanisms: macrodeformation (wound contraction drawing the edges together), microdeformation (cellular-level mechanical stress promoting granulation tissue), continuous exudate removal, and bioburden reduction. A sealed dressing connects to a vacuum pump that applies sub-atmospheric pressure (typically -125 mmHg) to the wound bed continuously or intermittently.

What is wound vac used for?

NPWT (often called wound vac) is used for chronic wounds (Stage 3 and 4 pressure injuries, diabetic foot ulcers, venous leg ulcers in select cases), acute surgical and traumatic wounds, skin graft bolstering, and increasingly for prophylactic use over high-risk closed surgical incisions. It is not appropriate for untreated infection, exposed vessels without barrier protection, malignancy in the wound bed, or necrotic tissue (debride first).

When should you NOT use NPWT?

Absolute contraindications include untreated osteomyelitis or wound infection, necrotic tissue with eschar (debride first), malignancy in the wound bed, exposed blood vessels or organs without barrier protection, and non-enteric or unexplored fistulas. Relative contraindications include therapeutic anticoagulation and inadequate vascular supply -- NPWT cannot heal an ischemic wound.

How is NPWT billed?

NPWT is billed using CPT codes 97605 through 97608, with the code selected by equipment type (durable vs. single-use disposable) and wound surface area (50 square centimeters or less, vs. greater than 50). The pump and supplies are billed separately under DME HCPCS codes (E2402 for the pump, A6550 for canisters, A6551 for dressing kits). Most payers require prior authorization and ongoing documentation of weekly progress.

A Therapy That Rewards Discipline

NPWT is one of the most effective tools in modern wound care -- when it is applied to the right wounds, set up correctly, and monitored consistently. The therapy is forgiving of patients and unforgiving of process. The wounds that fail under NPWT almost always fail because something upstream of the pump went wrong: a missed contraindication, an inadequate debridement, an untreated underlying ischemia, a seal that did not hold, or a clinical team that did not catch a deteriorating wound bed between dressing changes.

The clinical knowledge for NPWT is well-established and accessible. The operational complexity -- documentation, billing, DME tracking, prior authorization, multi-site continuity -- is where most wound care practices lose time and revenue. V3 Biomedical's platform supports NPWT end-to-end: documentation templates aligned with CPT requirements, integrated DME and supply tracking across 45+ wound care brands, prior authorization workflow support, and a unified patient record that follows the wound across hospital, outpatient, home health, and SNF settings.

[CTA: Request a V3 Biomedical Demo]

[Internal Link: V3 Biomedical platform overview -> /] [Internal Link: Products and supply management features -> /features/products] [Internal Link: Billing features -> /features/billing] [Internal Link: Diabetic foot ulcer clinical guide -> /blog/diabetic-foot-ulcer-clinical-guide] [Internal Link: Wound care CPT codes reference -> /blog/wound-care-cpt-codes-reference] [Internal Link: Pressure injury staging guide -> /blog/pressure-injury-stages] [Internal Link: Advanced wound care products survey -> /blog/advanced-wound-care-products] [Internal Link: Home health wound care -> /blog/home-health-wound-care] [Internal Link: SNF wound care -> /blog/snf-wound-care-guide] [Internal Link: Wound care documentation framework -> /blog/wound-care-documentation]

External References:

• Argenta LC, Morykwas MJ. Vacuum-assisted closure: a new method for wound control and treatment. Ann Plast Surg. 1997.
• CMS National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) for NPWT
• WOCN Society clinical guidelines on NPWT
• Manufacturer clinical application guidelines (current editions)